Asia Pacific Neurological Biomarker Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Others); Application (Alzheimer's Disease, Parkinson's Disease, Schizophrenia, Huntington's Disease, Spinal Muscular Atrophy, Others); End User (Pharmaceutical and Biotechnology Companies, Clinical Diagnostics, Research Organizations), and Country
Market Introduction
Neurological biomarkers are molecules present in the cerebral spinal fluid (CSF) or blood that support the diagnosis of brain disorders and monitor disease progression. This helps in the previous detection of disease, less invasive diagnostics, allows faster drug development, and is expected to be the effective treatment.
Get more information on this report :
Market Overview and Dynamics
The Asia Pacific neurological biomarker market is expected to reach US$ 2,620.63 million by 2027 from US$ 927.05 million in 2019; it is estimated to grow at a CAGR of 14.1% from 2020 to 2027. The growth of the market is attributed to key driving factors such as rising prevalence of neurological diseases and growing focus on neurological biomarker research. On the other hand, concerns associated with use of biomarkers such as the absence of pre-analytical tests are among the major factors hindering the market growth.
Key Market Segments
The Asia Pacific neurological biomarker market, based on product, is segmented into proteomics biomarker, genomics biomarker, metabolomics biomarker, imaging biomarker, and others. In 2019, the genomics biomarker segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest rate during the forecast period.
Based on application, the Asia Pacific neurological biomarker market is segmented into Alzheimer’s disease, Parkinson's disease, schizophrenia, Huntington's disease, spinal muscular atrophy, and others. The Alzheimer’s disease segment held the largest market share in 2019, and the market for the same segment is anticipated to grow at a significant rate during 2020 –2027.
The Asia Pacific neurological biomarker market, by end user, is segmented into pharmaceutical and biotechnology companies, clinical diagnostics, and research organizations. In 2019, the pharmaceutical and biotechnology companies segment held the largest share of the market. In addition, the market for the same segment is expected to grow at the fastest rate from 2020 to 2027.
Major Sources and Companies Listed
A Few of the primary and secondary sources associated with this report on the Asia Pacific neurological biomarker market are the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) and Biomarkers Across Neurodegenerative Diseases (BAND).
Reasons to buy the report
- Determine prospective investment areas based on a detailed trend analysis of the Asia Pacific neurological biomarker market over the next years.
- Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
- Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
- Identify the major channels driving the Asia Pacific neurological biomarker market, providing a clear picture of future opportunities that will help Analyze, resulting in revenue expansion.
- Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Asia Pacific neurological biomarker market.
ASIA PACIFIC NEUROLOGICAL BIOMARKER SEGMENTATION
By Product
- Proteomics Biomarker
- Genomics Biomarker
- Metabolomics Biomarker
- Imaging Biomarker
- Others
By Application
- Alzheimer’s Disease
- Parkinson's Disease
- Schizophrenia
- Huntington's Disease
- Spinal Muscular Atrophy
- Others
By End User
- Pharmaceutical and Biotechnology Companies
- Clinical Diagnostics
- Research Organizations
By Country
- India
- China
- Australia
- South Korea
- Japan
- Rest of Asia Pacific
Company Profiles
- Thermo Fisher Scientific Inc.
- Abbott
- Bio-Rad Laboratories Inc.
- QIAGEN
- Immunarray Pvt. Ltd.
- Quest Diagnostics Incorporated
- Perkin Elmer, Inc
- MERCK KGaA
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Neurological Biomarker Market – By Product
1.3.2 Asia Pacific Neurological Biomarker Market – By Application
1.3.3 Asia Pacific Neurological Biomarker Market – By End User
1.3.4 Asia Pacific Neurological Biomarker Market – By Country
2. Neurological Biomarker Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Neurological Biomarker Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific– PEST Analysis
4.3 Expert Opinion
5. Neurological Biomarker Market – Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of Neurological Diseases
5.1.2 Growing Focus on Neurological Biomarker Research
5.2 Key Market Restraints
5.2.1 Concerns Associated with Biomarkers
5.3 Key Market Opportunities
5.3.1 Increasing Awareness of Neurological Diseases Coupled with Developing Healthcare Infrastructure
5.4 Future Trends
5.4.1 The Rising Trend of Precision/Personalized Healthcare
5.5 Impact analysis
6. Neurological Biomarker Market – Asia Pacific Analysis
6.1 Asia Pacific Neurological Biomarker Market Revenue Forecast and Analysis
7. Neurological Biomarker Market Analysis– by Product
7.1 Overview
7.2 Neurological Biomarker Market Share, By Product, 2019 & 2027 (%)
7.3 Proteomics Biomarker
7.3.1 Overview
7.3.2 Proteomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.4 Genomics Biomarker
7.4.1 Overview
7.4.2 Genomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Metabolomics Biomarker
7.5.1 Overview
7.5.2 Metabolomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Imaging Biomarker
7.6.1 Overview
7.6.2 Imaging Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.7 Others
7.7.1 Overview
7.7.2 Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. Neurological Biomarker Market Analysis– by Application
8.1 Overview
8.2 Neurological Biomarker Market Share, By Application, 2019 & 2027 (%)
8.3 Alzheimer’s Disease
8.3.1 Overview
8.3.2 Alzheimer’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Parkinson’s Disease
8.4.1 Overview
8.4.2 Parkinson’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Schizophrenia
8.5.1 Overview
8.5.2 Schizophrenia Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Huntington's Disease
8.6.1 Overview
8.6.2 Huntington's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Spinal Muscular Atrophy
8.7.1 Overview
8.7.2 Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Others
8.8.1 Overview
8.8.2 Others Market Revenue and Forecasts to 2027 (US$ Mn)
9. Neurological Biomarker Market Analysis– by End User
9.1 Overview
9.2 Neurological Biomarker Market Share, By End User, 2019 & 2027 (%)
9.3 Pharmaceutical and Biotechnology Companies
9.3.1 Overview
9.3.2 Pharmaceutical and Biotechnology Companies Market Revenue and Forecasts to 2027 (US$ Mn)
9.4 Clinical Diagnostics
9.4.1 Overview
9.4.2 Clinical Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Research Organizations
9.5.1 Overview
9.5.2 Research Organizations Market Revenue and Forecasts to 2027 (US$ Mn)
10. Neurological Biomarker Market Analysis and Forecasts To 2027 – Asia Pacific Analysis
10.1 Asia Pacific: Neurological Biomarker Market
10.1.1 Overview
10.1.2 Asia Pacific: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.3 Asia Pacific: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)
10.1.4 Asia Pacific: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)
10.1.5 Asia Pacific: Neurological Biomarker Market, by End-User, 2018–2027 (USD Million)
10.1.6 Asia Pacific: Neurological Biomarker Market, by Country, 2019& 2027 (%)
10.1.7 China: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.1 China: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.2 China: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)
10.1.7.3 China: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)
10.1.7.4 China: Neurological Biomarker Market, by End-User, 2018–2027 (USD Million)
10.1.8 Japan: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.1 Japan: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.2 Japan: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)
10.1.8.3 Japan: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)
10.1.8.4 Japan: Neurological Biomarker Market, by End-User, 2018–2027 (USD Million)
10.1.9 India: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.1 India: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.2 India: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)
10.1.9.3 India: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)
10.1.9.4 India: Neurological Biomarker Market, by End User, 2018–2027 (USD Million)
10.1.10 South Korea: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.10.1 South Korea: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.10.2 South Korea: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)
10.1.10.3 South Korea: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)
10.1.10.4 South Korea: Neurological Biomarker Market, by End User, 2018–2027 (USD Million)
10.1.11 Australia: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.11.1 Australia: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.11.2 Australia: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)
10.1.11.3 Australia: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)
10.1.11.4 Australia: Neurological Biomarker Market, by End User, 2018–2027 (USD Million)
11. Impact of COVID-19 Pandemic on Asia Pacific Neurological Biomarker Market
11.1 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
12. Company Profiles
12.1 Thermo Fisher Scientific Inc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Abbott
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Bio-Rad Laboratories Inc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 QIAGEN
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Immunarray Pvt. Ltd.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Quest Diagnostics Incorporated
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Perkin Elmer, Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 MERCK KGaA
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 2. Asia Pacific Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 3. Asia Pacific Neurological Biomarker Market, by End-User– Revenue and Forecast to 2027 (USD Million)
Table 4. China Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 5. China Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 6. China Neurological Biomarker Market, by End-User– Revenue and Forecast to 2027 (USD Million)
Table 7. Japan Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 8. Japan Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 9. Japan Neurological Biomarker Market, by End-User– Revenue and Forecast to 2027 (USD Million)
Table 10. India Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 11. India Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 12. India Neurological Biomarker Market, by End User– Revenue and Forecast to 2027 (USD Million)
Table 13. South Korea Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 14. South Korea Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 15. South Korea Neurological Biomarker Market, by End User– Revenue and Forecast to 2027 (USD Million)
Table 16. Australia Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 17. Australia Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 18. Australia Neurological Biomarker Market, by End User– Revenue and Forecast to 2027 (USD Million)
Table 19. Glossary of Terms, Neurological Biomarker Market
LIST OF FIGURES
Figure 1. Neurological Biomarker Market Segmentation
Figure 2. Neurological Biomarker Market – By Country
Figure 3. Asia Pacific Neurological Biomarker Market Overview
Figure 4. Genomic Biomarkers Segment Held Largest Share of Neurological Biomarker Market
Figure 5. Asia Pacific Neurological Biomarker Market- Leading Country Markets (US$ Million)
Figure 6. Asia Pacific PEST Analysis
Figure 7. Expert Opinion
Figure 8. Neurological Biomarker Market Impact Analysis of Driver and Restraint
Figure 9. Asia Pacific Neurological Biomarker Market – Revenue Forecast and Analysis – 2019- 2027
Figure 10. Neurological Biomarker Market Share, by Product, 2019 & 2027 (%)
Figure 11. Proteomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Genomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. Metabolomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. Imaging Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. Neurological Biomarker Market Share, by Application, 2019 & 2027 (%)
Figure 17. Alzheimer’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Parkinson’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. Schizophrenia Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. Huntington's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. Neurological Biomarker Market Share, by End User, 2019 & 2027 (%)
Figure 24. Pharmaceutical and Biotechnology Companies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Clinical Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. Research Organizations Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 27. Asia Pacific: Neurological Biomarker Market, by Key Country – Revenue (2019) (USD Million)
Figure 28. Asia Pacific Neurological Biomarker Market Revenue and Forecast to 2027 (USD Million)
Figure 29. China: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
Figure 30. Japan: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
Figure 31. India: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
Figure 32. South Korea: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
Figure 33. Australia: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
Figure 34. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
- Thermo Fisher Scientific Inc.
- Abbott
- Bio-Rad Laboratories Inc.
- QIAGEN
- Immunarray Pvt. Ltd.
- Quest Diagnostics Incorporated
- Perkin Elmer, Inc
- MERCK KGaA
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific neurological biomarkers market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific neurological biomarkers market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.